Investors seeking to outperform the market often focus on hand-picking stocks. Selecting the right ones has proven to be a key factor in boosting wealth.
The closing price of Madrigal Pharmaceuticals Inc (NASDAQ: MDGL) was $379.55 for the day, down -3.04% from the previous closing price of $391.43. In other words, the price has decreased by -$3.04 from its previous closing price. On the day, 0.55 million shares were traded. MDGL stock price reached its highest trading level at $391.2691 during the session, while it also had its lowest trading level at $374.5.
Ratios:
Our analysis of MDGL’s different ratios will help us gain a deeper understanding of the company. For the most recent quarter (mrq), Quick Ratio is recorded 4.78 and its Current Ratio is at 5.11. In the meantime, Its Debt-to-Equity ratio is 0.18 whereas as Long-Term Debt/Eq ratio is at 0.18.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for the company, B. Riley Securities on February 28, 2025, Upgraded its rating to Buy and sets its target price to $422 from $236 previously.
On February 27, 2025, H.C. Wainwright reiterated its Buy rating and also lowered its target price recommendation from $400 to $405.
Insider Transactions:
Also, insider trades can serve as a great indicator of what management thinks about the future direction of a stock’s price. A recent insider transaction in this stock occurred on Aug 18 ’25 when Kelley Shannon T sold 1,304 shares for $367.81 per share. The transaction valued at 479,627 led to the insider holds 9,173 shares of the business.
Shannon Kelley bought 458 shares of MDGL for $169,387 on Aug 18 ’25. On Aug 18 ’25, another insider, FRED CRAVES, who serves as the Former Director of the company, bought 2,000 shares for $382.24 each.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, MDGL now has a Market Capitalization of 8459789824 and an Enterprise Value of 8051513856. For the stock, the TTM Price-to-Sale (P/S) ratio is 16.41 while its Price-to-Book (P/B) ratio in mrq is 12.12. Its current Enterprise Value per Revenue stands at 15.617 whereas that against EBITDA is -26.108.
Stock Price History:
The Beta on a monthly basis for MDGL is -1.04, which has changed by 0.4816333 over the last 52 weeks, in comparison to a change of 0.14064062 over the same period for the S&P500. Over the past 52 weeks, MDGL has reached a high of $393.76, while it has fallen to a 52-week low of $200.63. The 50-Day Moving Average of the stock is 20.82%, while the 200-Day Moving Average is calculated to be 20.25%.
Shares Statistics:
MDGL traded an average of 364.29K shares per day over the past three months and 451780 shares per day over the past ten days. A total of 22.22M shares are outstanding, with a floating share count of 20.16M. Insiders hold about 9.57% of the company’s shares, while institutions hold 105.90% stake in the company. Shares short for MDGL as of 1753920000 were 3980199 with a Short Ratio of 10.93, compared to 1751241600 on 3966696. Therefore, it implies a Short% of Shares Outstanding of 3980199 and a Short% of Float of 20.76.
Earnings Estimates
Current recommendations for the stock of the company come from 13.0 analysts. The consensus estimate for the next quarter is -$1.4, with high estimates of $0.53 and low estimates of -$7.84.
Analysts are recommending an EPS of between -$5.39 and -$14.83 for the fiscal current year, implying an average EPS of -$8.98. EPS for the following year is $4.47, with 14.0 analysts recommending between $17.73 and -$6.14.
Revenue Estimates
It is expected that $90B in revenue will be generated in the current quarter, according to 14 analysts. It ranges from a high estimate of $256.71M to a low estimate of $228.75M. As of the current estimate, Madrigal Pharmaceuticals Inc’s year-ago sales were $62.17MFor the next quarter, 14 analysts are estimating revenue of $281.29M. There is a high estimate of $301.18M for the next quarter, whereas the lowest estimate is $254.62M.
A total of 14 analysts have provided revenue estimates for MDGL’s current fiscal year. The highest revenue estimate was $907.93M, while the lowest revenue estimate was $833.43M, resulting in an average revenue estimate of $875.47M. In the same quarter a year ago, actual revenue was $180.13MBased on 13 analysts’ estimates, the company’s revenue will be $1.4B in the next fiscal year. The high estimate is $1.7B and the low estimate is $1.15B.
